Vera Therapeutics price target raised to $21 from $16 at Wedbush

Wedbush raised the firm’s price target on Vera Therapeutics to $21 from $16 and keeps a Neutral rating on the shares. Vera’s atacicept demonstrated continued eGFR stabilization at week 72 in the open-label extension phase of the Phase 2b ORIGIN study, the analyst tells investors in a research note. The key unanswered question remains how the APRIL-targeted agents will differentiate in final data sets, the firm says.